ABVC BioPharma (ABVC BioPharma) Interest Expense : $-2.49 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is ABVC BioPharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ABVC BioPharma's interest expense for the three months ended in Dec. 2023 was $ -1.10 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.49 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ABVC BioPharma's Operating Income for the three months ended in Dec. 2023 was $ -1.96 Mil. ABVC BioPharma's Interest Expense for the three months ended in Dec. 2023 was $ -1.10 Mil. ABVC BioPharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ABVC BioPharma Interest Expense Historical Data

The historical data trend for ABVC BioPharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABVC BioPharma Interest Expense Chart

ABVC BioPharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.48

-0.41

-0.23

-0.29

-2.49

ABVC BioPharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.13	-0.06	-0.12	-1.22	-1.10

ABVC BioPharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.49 Mil.

ABVC BioPharma (NAS:ABVC) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ABVC BioPharma's Interest Expense for the three months ended in Dec. 2023 was $-1.10 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-1.96 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $0.41 Mil.

ABVC BioPharma's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

ABVC BioPharma did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

ABVC BioPharma (ABVC BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABVC BioPharma Inc (NAS:ABVC) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

44370 Old Warm Springs Boulevard, Fremont, CA, USA, 94538

Website

https://www.abvcpharma.com

ABVC BioPharma Inc is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

Executives

Shuling Jiang	director, 10 percent owner	44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Shih-chen Tseng	director	5F., NO. 41-1, LN. 12, SINDONG ST., SONGSHAN DIST, TAIPEI CITY F5 105065
Yoshinobu Odaira	director	4823 DUNDAS STREET, THOMDALE, LONDON X0 N6P 1J1
Norimi Sakamoto	director	4823 DUNDAS STREET, THRONDALE, LONDON X0 N6P 1J1
Shin-yu Miao	director	NO. 25-12, AMLIN RD., XITUN DIST., TAICHUNG CITY F5 407676
Tsung Shann Jiang	director, officer: CSO and Director	1197 LA PLURISSIMA PL, FREMONT CA 94539
Eugene Jiang	director, officer: Chairman of the Board & CBO	1197 LA PLURISSIMA PL, FREMONT CA 94539
Chang-jen Jiang	director	1197 LA PLURISSIMA PL, FREMONT CA 94539
Yen-hsin Chou	director	13F. NO. 2, MEISHU E. 8TH ST.,, GUSHAN DIST., KAOHSIUNG CITY F5 804413
Chi-hsin Richard King	officer: Chief Scientific Officer	11907 GRANT PLACE, SAINT LOUIS MO 63131
Howard Doong	officer: Chief Executive Officer	44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Chihliang An	officer: Chief Financial Officer	32458 JEAN DR, UNION CITY CA 94587
Tsang Ming Jiang	director	1197 LA PURISSIMA PL, FREMONT CA 94539
Shulamit Lazar	director, 10 percent owner, officer: President,Secretary,Treasurer	8605 SANTA MONICA BOULEVARD, SUITE 41336, LOS ANGELES CA 90069
Kevin Patrick Stolz	officer: CFO & Controller	2701 CAMBRIDGE COURT, SUITE 100, AUBURN HILLS MI 48326